Ophthalmology | Research by Prof. Liang Jianhong and Prof. Cheng Yong Published in Ophthalmology
梁建宏、程湧团队关于早产儿视网膜病变治疗成果在权威期刊发表

2024-03-21

A study titled "Conbercept Versus Laser for the Treatment of Infants with Zone II Retinopathy of Prematurity" was published in the authoritative journal Ophthalmology (IF: 13.7) in January by a joint team led by Professor Liang Jianhong, Director of the Ophthalmology Department of Peking University People's Hospital (PKUPH), and Professor Cheng Yong from PKUPH, Professor Wang Yusheng from Xijing Hospital of Air Force Military Medical University of PLA (AFMU), and Professor Xiang Daoman from Guangzhou Women and Children's Medical Center. Dr. Liu Kailin from PKUPH is an additional co-first author. The study received support from the Beijing Science and Technology Plan project and the Beijing Bethune Charitable Foundation, among other projects.

Retinopathy of prematurity (ROP) is a condition affecting the eyes of prematurely born infants,those weighing less than 3 pounds at birth. It occurs due to the abnormal growth of blood vessels in the retina, the light-sensitive tissue at the back of the eye. Recognized by the World Health Organization as a preventable cause of blindness in infants, ROP poses a significant risk to the visual health of premature babies.

According to the research, laser photocoagulation, which removes excessive angiogenic stimuli originating from the avascular peripheral retina and prevents retinal detachment effectively, has been the standard treatment for ROP. Compared with laser therapy, the use of anti-VEGF agents has advantages such as the convenience of the procedure and continued growth of the physiological retinal vasculature. Conbercept (KH902, Chengdu Kanghong Biotech Co) is a novel recombinant fusion protein with high affinity for all VEGF isoforms and placental growth factors. Conbercept has been approved in China for the treatment of multiple retinal vascular disorders.，

Paper Link: https://doi.org/10.1016/j.ophtha.2024.01.006